Loading clinical trials...

Multiple-dose Pharmacokinetics of Ceftaroline During Continuous and Intermittent Renal Replacement Therapy in Patients Requiring Renal Replacement Therapy | Clinical Trials | Clareo Health

UNKNOWNPHASE4

Multiple-dose Pharmacokinetics of Ceftaroline During Continuous and Intermittent Renal Replacement Therapy in Patients Requiring Renal Replacement Therapy

NCT02007122•Medical University of Vienna

View on ClinicalTrials.gov

Summary

The study will be conducted to investigate the pharmacokinetics of ceftaroline during continuous and intermittent renal replacement therapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age \>18 years, able to give written informed consent
•Suspected or proven bacterial infection requiring parenteral antibiotic therapy.
•Renal replacement therapy (continuous or intermittent)

Exclusion Criteria

•Known hypersensitivity to ceftaroline or other cephalosporins, or severe hypersensitivity (anaphylactic reaction) to beta-lactam antibacterial agents.
•An expected survival of less than two days.
•Known pregnancy
•Coadministration of valproic acid or probenecid, which cannot be discontinued for the duration of the study
•Ceftaroline as monotherapy for resistent species or fungal infections.
•Other reasons oposing the study participation on the discretion of the investigators

Locations (1)

Medical University of Vienna

Vienna, Austria

Key Dates

Start Date

December 1, 2013

Primary Completion Date

November 1, 2022

Completion Date

March 1, 2023

Last Updated

April 14, 2022

Enrollment

ESTIMATED participants

Conditions

Infection During Renal Replacement Therapy

Interventions

Ceftaroline in CRRT

OTHER

Ceftaroline in IRRT

OTHER

Contacts

Florian Thalhammer, Prof. MD

CONTACT

0043 1 40400 florian.thalhammer@meduniwien.ac.at